+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Global Antibody Therapeutics Market by Format (Antibody Fragment, Bispecific Antibody, Monoclonal Antibody), Route of Administration (Intravenous, Subcutaneous), Source, Disease Areas, End User - Forecast 2024-2030

  • PDF Icon

    Report

  • 188 Pages
  • March 2024
  • Region: Global
  • 360iResearch™
  • ID: 5924893
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Antibody Therapeutics Market size was estimated at USD 248.79 billion in 2023, USD 285.77 billion in 2024, and is expected to grow at a CAGR of 14.89% to reach USD 657.50 billion by 2030.

Antibody therapeutics are a class of medical treatments that employ antibodies to mimic or enhance the immune system's ability to fight diseases. The precision of antibody therapeutics allows for tailored treatments that provide high specificity and lower toxicity profiles than conventional drugs, making them effective in treating various conditions, including cancers, autoimmune diseases, and infectious diseases. The increasing incidences of chronic diseases and increased healthcare expenditure globally have increased the adoption of antibody therapeutics. However, high costs associated with development and lengthy and complex regulatory approvals limit the penetration of antibody therapeutics. Nevertheless, advancements in medical technology are leading to more productive antibody production. In addition, the emergence of next-generation antibodies and supportive government initiatives for cancer care and treatments are expected to offer potential opportunities for the antibody therapeutics market.

Regional Insights

In the Americas, antibody therapeutics market exhibit robust growth supported by a well-established R&D ecosystem, extensive patent portfolio, and high healthcare expenditure. Furthermore, the Americas includes numerous biopharmaceutical giants, which dedicate substantial resources to developing monoclonal antibodies and novel drug discovery. The Asia-Pacific region experienced a surge in the need for antibody therapeutics due to a growing healthcare infrastructure and increased incidences of chronic disease. Moreover, the Asia-Pacific region is witnessing growth in the antibody therapeutics market owing to the advances in personalized medicine and antibody development, supported by its strong research institutions and supportive government policies. Given their strong pharmaceutical industry, extensive research initiatives, and comprehensive intellectual property rights framework, European Union countries are pivotal in the antibody therapeutics landscape. In addition, countries in the Middle East and Africa are investing in state-of-the-art medical facilities and healthcare innovation.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Antibody Therapeutics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Antibody Therapeutics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Antibody Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., AbCellera Biologics Inc., Adaptimmune Therapeutics PLC, ADC Therapeutics SA, Aenova Holding GmbH, Almac Group Limited, Amgen Inc., Antikor Biopharma, Argenx SE, Astellas Pharma Inc., AstraZeneca PLC, Baxter International Inc., Bayer AG, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Biogen Inc., BioNTech SE, Bristol-Myers Squibb Company, Confo Therapeutics, DH Life Sciences, LLC, DotBio Pte. Ltd., Eli Lilly and Company, Emergent BioSolutions Inc., Evonik Industries AG, F. Hoffmann-La Roche Ltd., GE HealthCare Technologies, Inc.,, Genmab A/S, GlaxoSmithKline PLC, Grifols, S.A., Incyte Corporation, iTeos Therapeutics, Inc., Johnson & Johnson Services, Inc., Merck KGaA, Merus N.V., MoonLake Immunotherapeutics AG, MorphoSys AG, Novartis AG, Novo Nordisk A/S, Numab Therapeutics AG, Pfizer Inc., PharmAbcine Inc., Pyxis Oncology, Inc., Regeneron Pharmaceuticals, Inc., SAB Biotherapeutics, Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Thermo Fisher Scientific Inc., TRIO Pharmaceuticals Inc., UCB S.A., and Xencor, Inc.

Market Segmentation & Coverage

This research report categorizes the Antibody Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Format
    • Antibody Fragment
    • Bispecific Antibody
    • Monoclonal Antibody
    • Polyclonal Antibody
  • Route of Administration
    • Intravenous
    • Subcutaneous
  • Source
    • Chimeric
    • Human
    • Humanized
  • Disease Areas
    • Autoimmune & Inflammatory Diseases
    • Hematology
    • Immunology
    • Neurology
    • Oncology
    • Osteology
  • End User
    • Hospitals
    • Long-term Care Facilities
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

  1. Market Penetration: It presents comprehensive information on the market provided by key players.
  2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
  3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
  4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
  5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

  1. What is the market size and forecast of the Antibody Therapeutics Market?
  2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Antibody Therapeutics Market?
  3. What are the technology trends and regulatory frameworks in the Antibody Therapeutics Market?
  4. What is the market share of the leading vendors in the Antibody Therapeutics Market?
  5. Which modes and strategic moves are suitable for entering the Antibody Therapeutics Market?

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Antibody Therapeutics Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising incidences of various cancers and infectious diseases
5.1.1.2. Increasing number of drug discovery activities worldwide
5.1.1.3. Government initiatives to promote access to antibody treatments and therapies
5.1.2. Restraints
5.1.2.1. Incidences of product recalls of antibody therapeutics coupled with strict approval guidelines
5.1.3. Opportunities
5.1.3.1. Advancements in the clinical development of antibody therapeutics
5.1.3.2. Ongoing approvals for novel antibody therapies and treatments
5.1.4. Challenges
5.1.4.1. Insufficient efficacy and adverse effects associated with various treatments
5.2. Market Segmentation Analysis
5.2.1. Format: Significant utilization of monoclonal antibodies due to numerous approvals by regulatory agencies for clinical use
5.2.2. Route of Administration: Growing usage of intravenous administration of antibody therapeutics
5.2.3. Source: Increasing use of human antibodies due to its biocompatible nature
5.2.4. Disease Areas: Proliferating use of antibody therapeutics for infectious diseases
5.2.5. End User: Evolving usage of antibody therapeutics in hospitals
5.3. Market Trend Analysis
5.3.1. Advanced R&D activities in antibody therapeutics backed by government funding and partnership activities by global established pharmaceutical companies in Americas
5.3.2. Growing burden of chronic and infectious diseases creating need for antibody therapeutics in the Asia-Pacific
5.3.3. Ongoing clinical trials coupled with expansion of biotech companies in the EMEA region
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Antibody Therapeutics Market, by Format
6.1. Introduction
6.2. Antibody Fragment
6.3. Bispecific Antibody
6.4. Monoclonal Antibody
6.5. Polyclonal Antibody
7. Antibody Therapeutics Market, by Route of Administration
7.1. Introduction
7.2. Intravenous
7.3. Subcutaneous
8. Antibody Therapeutics Market, by Source
8.1. Introduction
8.2. Chimeric
8.3. Human
8.4. Humanized
9. Antibody Therapeutics Market, by Disease Areas
9.1. Introduction
9.2. Autoimmune & Inflammatory Diseases
9.3. Hematology
9.4. Immunology
9.5. Neurology
9.6. Oncology
9.7. Osteology
10. Antibody Therapeutics Market, by End User
10.1. Introduction
10.2. Hospitals
10.3. Long-term Care Facilities
11. Americas Antibody Therapeutics Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States
12. Asia-Pacific Antibody Therapeutics Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam
13. Europe, Middle East & Africa Antibody Therapeutics Market
13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom
14. Competitive Landscape
14.1. FPNV Positioning Matrix
14.2. Market Share Analysis, By Key Player
14.3. Competitive Scenario Analysis, By Key Player
14.3.1. Merger & Acquisition
14.3.1.1. AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio
14.3.1.2. Pyxis Oncology to acquire Antibody Therapeutics Company Apexigen
14.3.1.3. Merck to Develop mAb Through USD 10.8 Billion Acquisition
14.3.2. Agreement, Collaboration, & Partnership
14.3.2.1. SystImmune and Bristol Myers Squibb Announce a Global Strategic Collaboration Agreement for the Development and Commercialization of BL-B01D1
14.3.2.2. AbbVie and BigHat Biosciences Announce Research Collaboration to Leverage Artificial Intelligence and Machine Learning to Discover Next-Generation Therapeutic Antibodies
14.3.2.3. Salipro Partners with Icosagen to Develop Monoclonal Antibody Therapies
14.3.2.4. AbCellera, Incyte Partner on Therapeutic Antibodies in Oncology
14.3.2.5. Genmab and argenx Enter Partnership to Advance Antibody Therapies in Immunology and Oncology
14.3.3. New Product Launch & Enhancement
14.3.3.1. U.S. FDA Approves TALVEY, a First-in-Class Bispecific Therapy for the Treatment of Patients with Heavily Pretreated Multiple Myeloma
14.3.4. Investment & Funding
14.3.4.1. MBrace Therapeutics Raises USD 85 Million Series B Financing to Advance Oncology Pipeline of Innovative Antibody Drug Conjugate Candidates
14.3.4.2. Crossbow Therapeutics Debuts with USD 80 Million in Series A Financing to Advance Antibody Therapeutics
14.3.4.3. Crossbow Therapeutics Debuts with USD 80 Million in Series A Financing to Advance Antibody Therapeutics
14.3.5. Award, Recognition, & Expansion
14.3.5.1. Japan Grants Patent for Bioarctic’s Parkinson’s Disease Antibody
15. Competitive Portfolio
15.1. Key Company Profiles
15.1.1. AbbVie Inc.
15.1.2. AbCellera Biologics Inc.
15.1.3. Adaptimmune Therapeutics PLC
15.1.4. ADC Therapeutics SA
15.1.5. Aenova Holding GmbH
15.1.6. Almac Group Limited
15.1.7. Amgen Inc.
15.1.8. Antikor Biopharma
15.1.9. Argenx SE
15.1.10. Astellas Pharma Inc.
15.1.11. AstraZeneca PLC
15.1.12. Baxter International Inc.
15.1.13. Bayer AG
15.1.14. Becton, Dickinson and Company
15.1.15. Bio-Rad Laboratories, Inc.
15.1.16. Biogen Inc.
15.1.17. BioNTech SE
15.1.18. Bristol-Myers Squibb Company
15.1.19. Confo Therapeutics
15.1.20. DH Life Sciences, LLC
15.1.21. DotBio Pte. Ltd.
15.1.22. Eli Lilly and Company
15.1.23. Emergent BioSolutions Inc.
15.1.24. Evonik Industries AG
15.1.25. F. Hoffmann-La Roche Ltd.
15.1.26. GE HealthCare Technologies, Inc.,
15.1.27. Genmab A/S
15.1.28. GlaxoSmithKline PLC
15.1.29. Grifols, S.A.
15.1.30. Incyte Corporation
15.1.31. iTeos Therapeutics, Inc.
15.1.32. Johnson & Johnson Services, Inc.
15.1.33. Merck KGaA
15.1.34. Merus N.V.
15.1.35. MoonLake Immunotherapeutics AG
15.1.36. MorphoSys AG
15.1.37. Novartis AG
15.1.38. Novo Nordisk A/S
15.1.39. Numab Therapeutics AG
15.1.40. Pfizer Inc.
15.1.41. PharmAbcine Inc.
15.1.42. Pyxis Oncology, Inc.
15.1.43. Regeneron Pharmaceuticals, Inc.
15.1.44. SAB Biotherapeutics, Inc.
15.1.45. Sanofi S.A.
15.1.46. Takeda Pharmaceutical Company Limited
15.1.47. Thermo Fisher Scientific Inc.
15.1.48. TRIO Pharmaceuticals Inc.
15.1.49. UCB S.A.
15.1.50. Xencor, Inc.
15.2. Key Product Portfolio
16. Appendix
16.1. Discussion Guide
16.2. License & Pricing
List of Figures
FIGURE 1. ANTIBODY THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 2. ANTIBODY THERAPEUTICS MARKET SIZE, 2023 VS 2030
FIGURE 3. ANTIBODY THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. ANTIBODY THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. ANTIBODY THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. ANTIBODY THERAPEUTICS MARKET DYNAMICS
FIGURE 7. ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2023 VS 2030 (%)
FIGURE 8. ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 10. ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2023 VS 2030 (%)
FIGURE 12. ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2023 VS 2030 (%)
FIGURE 14. ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
FIGURE 16. ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 20. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 25. ANTIBODY THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 26. ANTIBODY THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
List of Tables
TABLE 1. ANTIBODY THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. ANTIBODY THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
TABLE 6. ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY FRAGMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. ANTIBODY THERAPEUTICS MARKET SIZE, BY BISPECIFIC ANTIBODY, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. ANTIBODY THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODY, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. ANTIBODY THERAPEUTICS MARKET SIZE, BY POLYCLONAL ANTIBODY, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 11. ANTIBODY THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. ANTIBODY THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 14. ANTIBODY THERAPEUTICS MARKET SIZE, BY CHIMERIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. ANTIBODY THERAPEUTICS MARKET SIZE, BY HUMAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. ANTIBODY THERAPEUTICS MARKET SIZE, BY HUMANIZED, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
TABLE 18. ANTIBODY THERAPEUTICS MARKET SIZE, BY AUTOIMMUNE & INFLAMMATORY DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. ANTIBODY THERAPEUTICS MARKET SIZE, BY HEMATOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. ANTIBODY THERAPEUTICS MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. ANTIBODY THERAPEUTICS MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. ANTIBODY THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. ANTIBODY THERAPEUTICS MARKET SIZE, BY OSTEOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 25. ANTIBODY THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. ANTIBODY THERAPEUTICS MARKET SIZE, BY LONG-TERM CARE FACILITIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
TABLE 28. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 29. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 30. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
TABLE 31. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 32. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 33. ARGENTINA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
TABLE 34. ARGENTINA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 35. ARGENTINA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 36. ARGENTINA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
TABLE 37. ARGENTINA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 38. BRAZIL ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
TABLE 39. BRAZIL ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 40. BRAZIL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 41. BRAZIL ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
TABLE 42. BRAZIL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 43. CANADA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
TABLE 44. CANADA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 45. CANADA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 46. CANADA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
TABLE 47. CANADA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 48. MEXICO ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
TABLE 49. MEXICO ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 50. MEXICO ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 51. MEXICO ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
TABLE 52. MEXICO ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 59. ASIA-PACIFIC ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
TABLE 60. ASIA-PACIFIC ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 61. ASIA-PACIFIC ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 62. ASIA-PACIFIC ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
TABLE 63. ASIA-PACIFIC ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 64. ASIA-PACIFIC ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 65. AUSTRALIA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
TABLE 66. AUSTRALIA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 67. AUSTRALIA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 68. AUSTRALIA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
TABLE 69. AUSTRALIA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 70. CHINA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
TABLE 71. CHINA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 72. CHINA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 73. CHINA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
TABLE 74. CHINA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 75. INDIA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
TABLE 76. INDIA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 77. INDIA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 78. INDIA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
TABLE 79. INDIA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 80. INDONESIA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
TABLE 81. INDONESIA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 82. INDONESIA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 83. INDONESIA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
TABLE 84. INDONESIA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 85. JAPAN ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
TABLE 86. JAPAN ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 87. JAPAN ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 88. JAPAN ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
TABLE 89. JAPAN ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 90. MALAYSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
TABLE 91. MALAYSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 92. MALAYSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 93. MALAYSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
TABLE 94. MALAYSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 95. PHILIPPINES ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
TABLE 96. PHILIPPINES ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 97. PHILIPPINES ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 98. PHILIPPINES ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
TABLE 99. PHILIPPINES ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 100. SINGAPORE ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
TABLE 101. SINGAPORE ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 102. SINGAPORE ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 103. SINGAPORE ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
TABLE 104. SINGAPORE ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 105. SOUTH KOREA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
TABLE 106. SOUTH KOREA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 107. SOUTH KOREA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 108. SOUTH KOREA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
TABLE 109. SOUTH KOREA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 110. TAIWAN ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
TABLE 111. TAIWAN ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 112. TAIWAN ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 113. TAIWAN ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
TABLE 114. TAIWAN ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 115. THAILAND ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
TABLE 116. THAILAND ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 117. THAILAND ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 118. THAILAND ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
TABLE 119. THAILAND ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 120. VIETNAM ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
TABLE 121. VIETNAM ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 122. VIETNAM ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 123. VIETNAM ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
TABLE 124. VIETNAM ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 125. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
TABLE 126. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 127. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 128. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
TABLE 129. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 130. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 131. DENMARK ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
TABLE 132. DENMARK ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 133. DENMARK ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 134. DENMARK ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
TABLE 135. DENMARK ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 136. EGYPT ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
TABLE 137. EGYPT ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 138. EGYPT ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 139. EGYPT ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
TABLE 140. EGYPT ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 141. FINLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
TABLE 142. FINLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 143. FINLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 144. FINLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
TABLE 145. FINLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 146. FRANCE ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
TABLE 147. FRANCE ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 148. FRANCE ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 149. FRANCE ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
TABLE 150. FRANCE ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 151. GERMANY ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
TABLE 152. GERMANY ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 153. GERMANY ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 154. GERMANY ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
TABLE 155. GERMANY ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 156. ISRAEL ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
TABLE 157. ISRAEL ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 158. ISRAEL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 159. ISRAEL ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
TABLE 160. ISRAEL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 161. ITALY ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
TABLE 162. ITALY ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 163. ITALY ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 164. ITALY ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
TABLE 165. ITALY ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 166. NETHERLANDS ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
TABLE 167. NETHERLANDS ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 168. NETHERLANDS ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 169. NETHERLANDS ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
TABLE 170. NETHERLANDS ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 171. NIGERIA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
TABLE 172. NIGERIA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 173. NIGERIA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 174. NIGERIA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
TABLE 175. NIGERIA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 176. NORWAY ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
TABLE 177. NORWAY ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 178. NORWAY ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 179. NORWAY ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
TABLE 180. NORWAY ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 181. POLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
TABLE 182. POLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 183. POLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 184. POLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
TABLE 185. POLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 186. QATAR ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
TABLE 187. QATAR ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 188. QATAR ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 189. QATAR ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
TABLE 190. QATAR ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 191. RUSSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
TABLE 192. RUSSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 193. RUSSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 194. RUSSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
TABLE 195. RUSSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 196. SAUDI ARABIA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
TABLE 197. SAUDI ARABIA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 198. SAUDI ARABIA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 199. SAUDI ARABIA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
TABLE 200. SAUDI ARABIA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 201. SOUTH AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
TABLE 202. SOUTH AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 203. SOUTH AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 204. SOUTH AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
TABLE 205. SOUTH AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 206. SPAIN ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
TABLE 207. SPAIN ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 208. SPAIN ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 209. SPAIN ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
TABLE 210. SPAIN ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 211. SWEDEN ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
TABLE 212. SWEDEN ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 213. SWEDEN ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 214. SWEDEN ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
TABLE 215. SWEDEN ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 216. SWITZERLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
TABLE 217. SWITZERLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 218. SWITZERLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 219. SWITZERLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
TABLE 220. SWITZERLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 221. TURKEY ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
TABLE 222. TURKEY ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 223. TURKEY ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 224. TURKEY ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
TABLE 225. TURKEY ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 226. UNITED ARAB EMIRATES ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
TABLE 227. UNITED ARAB EMIRATES ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 228. UNITED ARAB EMIRATES ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 229. UNITED ARAB EMIRATES ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
TABLE 230. UNITED ARAB EMIRATES ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 231. UNITED KINGDOM ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
TABLE 232. UNITED KINGDOM ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 233. UNITED KINGDOM ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 234. UNITED KINGDOM ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
TABLE 235. UNITED KINGDOM ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 236. ANTIBODY THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023
TABLE 237. ANTIBODY THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
TABLE 238. ANTIBODY THERAPEUTICS MARKET LICENSE & PRICING

Companies Mentioned

  • AbbVie Inc.
  • AbCellera Biologics Inc.
  • Adaptimmune Therapeutics PLC
  • ADC Therapeutics SA
  • Aenova Holding GmbH
  • Almac Group Limited
  • Amgen Inc.
  • Antikor Biopharma
  • Argenx SE
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Baxter International Inc.
  • Bayer AG
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Biogen Inc.
  • BioNTech SE
  • Bristol-Myers Squibb Company
  • Confo Therapeutics
  • DH Life Sciences, LLC
  • DotBio Pte. Ltd.
  • Eli Lilly and Company
  • Emergent BioSolutions Inc.
  • Evonik Industries AG
  • F. Hoffmann-La Roche Ltd.
  • GE HealthCare Technologies, Inc.,
  • Genmab A/S
  • GlaxoSmithKline PLC
  • Grifols, S.A.
  • Incyte Corporation
  • iTeos Therapeutics, Inc.
  • Johnson & Johnson Services, Inc.
  • Merck KGaA
  • Merus N.V.
  • MoonLake Immunotherapeutics AG
  • MorphoSys AG
  • Novartis AG
  • Novo Nordisk A/S
  • Numab Therapeutics AG
  • Pfizer Inc.
  • PharmAbcine Inc.
  • Pyxis Oncology, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • SAB Biotherapeutics, Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
  • Thermo Fisher Scientific Inc.
  • TRIO Pharmaceuticals Inc.
  • UCB S.A.
  • Xencor, Inc.

Methodology

Loading
LOADING...

Table Information